Response Rates to PD-L1 and CTLA-4 Inhibition Are Shown to Be Low in Unselected Patients With MBC, Yet High Rates of Clinical Benefit Are Observed in TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.